B+
Bull case
25%
Probability
Target price
$6.06
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
KLRS
Kalaris TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Expanded early TH103 data and ongoing Phase 1b/2 dosing could support differentiation, while the stated cash runway allows execution through important clinical milestones. The principal upside depends on a credible 2027 preliminary readout and subsequent Phase 3 progression.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash declined from $118.0 million at December 31, 2025 to $93.5 million at June 30, 2026; future financing and dilution remain possible.
Momentum
74
Value
59
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.80 · Bull $6.06 · Bear $2.20Analysis 2026-09-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.71
Why
Momentum74 · Δ7d -
Value59 · Δ7d 0.0
Sentiment84 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Cash declined from $118.0 million at December 31, 2025 to $93.5 million at June 30, 2026; future financing and dilution remain possible.
- • Phase 1b/2 efficacy, safety, dosing, or enrollment outcomes may disappoint.
- • The company remains an early clinical-stage biotech with binary efficacy, safety, dosing, and regulatory risks.
Catalyst clock
2027-06-30
TH103 Phase 1b/2 preliminary data expected in 1H 2027 [#SEC-8K-2026-08-11]
Lead driver: Sentiment · See AI snapshot
Momentum
74
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
84
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 74.5 / Value 58.6 / Sentiment 83.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-01. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.80
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$86.49M
Beta
-0.10
Shares Out
23.81M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.76
Rev YoY
-100.0%
EPS YoY
-20.3%
Gross Margin
-
Op Margin
-
Net Debt
-$116.53M
Current Ratio
10.92
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data